Autoimmune Encephalitis Clinical Trial
Official title:
Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis
Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered
mental status or psychiatric symptoms, frequently associated with seizures, inflammatory
cerebrospinal fluid and in cases with prominent limbic involvement, typical magnetic
resonance imaging. Several autoantibodies (Ab) may be detected in AE, although its detection
is not mandatory to establish a diagnosis. These Ab mainly recognize different synaptic and
cell-surface proteins in the central nervous system, and are thought to be pathogenic as they
alter the normal location or function of its antigens.
The primary trigger of the immune response is unknown for most of AE. In addition to acquired
susceptibility, genetic predisposition may also be important in the pathogenesis of AE. Human
leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune
diseases, due to its genetic complexity and key role in the adaptive immune response. The aim
of the study is to describe HLA profile in three groups of autoimmune encephalitis and
related disorders: anti-LGI1, anti-CASPR2 and anti-GAD neurological diseases.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
| Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
| Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
| Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
| Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
| Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
| Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
| Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
| Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
| Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
| Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
| Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
| Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
| Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
| Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
| Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
| Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|